Intellia Therapeutics Inc (USD)
NTLA
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range11.64 | 12.24
52-Wk Range |
Last Close12.23
Mkt Cap (m)617.71
Dividend yield-
ISINUS45826J1051
Volume27,028
Exchange VenueNAS

Company Profile

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Key Information
Price/Earning-
Price/Book2.29
Price/Sales13.41
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 03/11/2017
Annual Report
en 31/12/2019

Financials

Income Statement
USD201420152016201720182019
Revenue (m)-6162630-
Operating Income (m)--13-32-70-91-
Net Income (m)--12-32-68-85-
Basic EPS--0.36-1.42-1.88-1.98-
Avg. Diluted Shares Outstanding (m)-34223643-
Balance Sheet
USD201420152016201720182019
Current Assets (m)1078281355325-
Non Current Assets (m)15182122-
Total Assets (m)1182299376347-
Current Liabilities (m)211313141-
Total Liabilities (m)------
Total Equity (m)867210301278-
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)--236-65-61-
Capital Expenditure (m)--3-6-10-6-
Figures are quoted in USD unless stated otherwise
-0.06 (-0.49%)
$
12.17
Last Price